
Philip E Baker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4559144/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
4	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
5	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
6	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
7	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
8	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
9	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214
10	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
11	High-flow nasal cannulae for respiratory support in adult intensive care patients. The Cochrane Library, 2017, 5, CD010172.	1.5	54
12	Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis. The Cochrane Library, 2019, 2019, .	1.5	38
13	High-flow nasal cannulae for respiratory support in adult intensive care patients. The Cochrane Library, 2021, 2021, CD010172.	1.5	32
14	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. Clinical Infectious Diseases, 2019, 68, 1265-1273.	2.9	26
15	Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. PLoS Neglected Tropical Diseases, 2020, 14, e0008783.	1.3	15
16	From proband to provider: is there an obligation to inform genetic relatives of actionable risks discovered through direct-to-consumer genetic testing?. Journal of Medical Ethics, 2020, , medethics-2020-106966.	1.0	3
17	Interventions to reduce body temperature to 35 âºC to 37 âºC in adults and children with traumatic brain injury. The Cochrane Library, 2020, 2020, CD006811.	1.5	1